Jump to navigation Jump to search
Clinical data
Routes of
ATC code
Legal status
Legal status
  • Schedule IV, Withdrawn from market
Pharmacokinetic data
Elimination half-life20 hours
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass231.257

WikiDoc Resources for Fenfluramine


Most recent articles on Fenfluramine

Most cited articles on Fenfluramine

Review articles on Fenfluramine

Articles on Fenfluramine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Fenfluramine

Images of Fenfluramine

Photos of Fenfluramine

Podcasts & MP3s on Fenfluramine

Videos on Fenfluramine

Evidence Based Medicine

Cochrane Collaboration on Fenfluramine

Bandolier on Fenfluramine

TRIP on Fenfluramine

Clinical Trials

Ongoing Trials on Fenfluramine at Clinical Trials.gov

Trial results on Fenfluramine

Clinical Trials on Fenfluramine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Fenfluramine

NICE Guidance on Fenfluramine


FDA on Fenfluramine

CDC on Fenfluramine


Books on Fenfluramine


Fenfluramine in the news

Be alerted to news on Fenfluramine

News trends on Fenfluramine


Blogs on Fenfluramine


Definitions of Fenfluramine

Patient Resources / Community

Patient resources on Fenfluramine

Discussion groups on Fenfluramine

Patient Handouts on Fenfluramine

Directions to Hospitals Treating Fenfluramine

Risk calculators and risk factors for Fenfluramine

Healthcare Provider Resources

Symptoms of Fenfluramine

Causes & Risk Factors for Fenfluramine

Diagnostic studies for Fenfluramine

Treatment of Fenfluramine

Continuing Medical Education (CME)

CME Programs on Fenfluramine


Fenfluramine en Espanol

Fenfluramine en Francais


Fenfluramine in the Marketplace

Patents on Fenfluramine

Experimental / Informatics

List of terms related to Fenfluramine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Fenfluramine is a drug that was part of the Fen-Phen anti-obesity medication (the other drug being phentermine). Also known as Pondimin, fenfluramine was introduced on the U.S. market in 1973. It is the racemic mixture of two enantiomers, dexfenfluramine and levofenfluramine. It is designed to increase the level of the neurotransmitter serotonin, a chemical that regulates mood, appetite and other functions. Fenfluramine causes the release of serotonin by disrupting vesicular storage of the neurotransmitter, and reversing serotonin transporter function.[1] The end result is a feeling of fullness and loss of appetite.

The drug was withdrawn from the U.S. market in 1997 after reports of heart valve disease and pulmonary hypertension, including a condition known as cardiac fibrosis. After the US withdrawal of fenfluramine, it was also withdrawn from other markets around the world.

The distinctive valvular abnormality seen with fenfluramine is a thickening of the leaflet and chordae tendinae. Roth[2] suggested a mechanism by which fenfluramine damaged the valves. Heart valves also have serotonin receptors, which regulate their growth. He reported that fenfluramine and its active metabolite norfenfluramine stimulated the serotonin receptors 5-hydroxytryptamine (5-HT). In particular norfenfluramine is a potent agonist (stimulant) of 5-HT2B receptors. These receptors are plentiful in human cardiac valves and appear to be essential for normal cardiac development. Roth suggested that the mechanism by which fenfluramine causes damage is through inappropriately stimulating the valve cells to divide. This valve damage is found in other drugs that act on 5-HT2B receptors.


  1. Nestler, Eric J. "Molecular Neuropharmacology: A Foundation for Clinical Neuroscience" McGraw-Hill, 2001.
  2. Roth, B Drugs and Valvular Heart Disease. N Engl J Med 2007;356:6 PMID 17202450

External links

Template:Phenethylamines Template:Antiobesity preparations


Template:WikiDoc Sources